Research Analysts Issue Forecasts for GPCR Q4 Earnings

Structure Therapeutics Inc. (NASDAQ:GPCR) – Equities research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for Structure Therapeutics in a report released on Monday, March 3rd. Leerink Partnrs analyst D. Risinger forecasts that the company will earn $2.58 per share for the quarter. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.46) EPS and FY2028 earnings at ($1.53) EPS.

A number of other equities research analysts have also issued reports on the stock. William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. JMP Securities restated a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Stifel Nicolaus started coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

GPCR opened at $22.57 on Wednesday. Structure Therapeutics has a 1 year low of $19.61 and a 1 year high of $62.74. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of -30.50 and a beta of -2.75. The stock’s 50 day simple moving average is $26.22 and its 200 day simple moving average is $33.29.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Structure Therapeutics in the 4th quarter worth approximately $3,091,000. GF Fund Management CO. LTD. purchased a new stake in Structure Therapeutics during the fourth quarter valued at approximately $34,000. Woodline Partners LP raised its position in Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock worth $9,055,000 after acquiring an additional 2,328 shares during the period. Vestal Point Capital LP boosted its stake in shares of Structure Therapeutics by 50.0% during the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after acquiring an additional 575,000 shares during the last quarter. Finally, Twinbeech Capital LP grew its position in shares of Structure Therapeutics by 34.3% during the 4th quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock valued at $767,000 after acquiring an additional 7,220 shares during the period. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.